Demographics and characteristics of patients with AA at the time of diagnosis, treated with ALZ
| N = 61 patients . | Value . |
|---|---|
| Age, median (range), y | 52 (18-81) |
| 18-30 | 13 (21) |
| 30-65 | 35 (58) |
| ≥65 | 13 (21) |
| Male gender, n (%) | 34 (56) |
| Disease severity, n (%) | |
| Nonsevere | 15 (24) |
| Severe | 37 (61) |
| Very severe | 9 (15) |
| PNH clone positive, n (%) | 34 (56) |
| Complete blood count at diagnosis, median (range) | |
| Hemoglobin, g/dL | 7.5 (4.1-11.3) |
| Reticulocytes, ×109/L | 27 (1.3-100) |
| Neutrophils, ×109/L | 0.65 (0.05-6.78) |
| Lymphocytes, ×109/L | 1.6 (0.23-5.54) |
| Platelets, ×109/L | 11 (2-576) |
| Complete blood count before alemtuzumab, median (range) | |
| Hemoglobin, g/dL | 7.3 (4.3-11.3) |
| Reticulocytes, ×109/L | 33 (1.22-104) |
| Neutrophils, ×109/L | 0.53 (0.05-3.4) |
| Lymphocytes, ×109/L | 1.52 (0.59-3.3) |
| Platelets, ×109/L | 11 (1-326) |
| Follow-up time, median (range), mo | 47 (4-153) |
| N = 61 patients . | Value . |
|---|---|
| Age, median (range), y | 52 (18-81) |
| 18-30 | 13 (21) |
| 30-65 | 35 (58) |
| ≥65 | 13 (21) |
| Male gender, n (%) | 34 (56) |
| Disease severity, n (%) | |
| Nonsevere | 15 (24) |
| Severe | 37 (61) |
| Very severe | 9 (15) |
| PNH clone positive, n (%) | 34 (56) |
| Complete blood count at diagnosis, median (range) | |
| Hemoglobin, g/dL | 7.5 (4.1-11.3) |
| Reticulocytes, ×109/L | 27 (1.3-100) |
| Neutrophils, ×109/L | 0.65 (0.05-6.78) |
| Lymphocytes, ×109/L | 1.6 (0.23-5.54) |
| Platelets, ×109/L | 11 (2-576) |
| Complete blood count before alemtuzumab, median (range) | |
| Hemoglobin, g/dL | 7.3 (4.3-11.3) |
| Reticulocytes, ×109/L | 33 (1.22-104) |
| Neutrophils, ×109/L | 0.53 (0.05-3.4) |
| Lymphocytes, ×109/L | 1.52 (0.59-3.3) |
| Platelets, ×109/L | 11 (1-326) |
| Follow-up time, median (range), mo | 47 (4-153) |